Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL433060 | 0.98 | PTGDR2 (0.35) | PTGDR2 | |
| SCHEMBL7838303 | 0.98 | PTGDR2 (0.35) | PTGDR2 | |
| SCHEMBL19595794 | 0.96 | ABCC8 (0.31) | F2RL1 | |
| SCHEMBL4075115 | 0.92 | PTGS1 (0.31) | — | |
| SCHEMBL27657802 | 0.83 | SLC6A2 (0.39) | — | |
| SCHEMBL3770026 | 0.83 | ESR2 (0.36) | — | |
| SCHEMBL3764985 | 0.83 | ESR2 (0.36) | — | |
| SCHEMBL3766569 | 0.79 | DPP4 (0.31) | — | |
| SCHEMBL3758994 | 0.79 | ESR1 (0.41) | — | |
| SCHEMBL3769275 | 0.79 | ALDH1A1 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10550089-B2 | Inhibitors of protease-activated receptor-2 | HEPTARES THERAPEUTICS LIMITED (GB) | 2020-02-04 | — | — | US | disclosed |
| US-20190144394-A1 | INHIBITORS OF PROTEASE-ACTIVATED RECEPTOR-2 | HEPTARES THERAPEUTICS LIMITED (GB) | 2019-05-16 | — | — | US | disclosed |
| EP-3455212-A1 | INHIBITORS OF PROTEASE-ACTIVATED RECEPTOR-2 | Heptares Therapeutics Limited (GB) | 2019-03-20 | — | — | EP | disclosed |
| WO-2017194716-A1 | INHIBITORS OF PROTEASE-ACTIVATED RECEPTOR-2 | ASTRAZENECA AB (SE) | 2017-11-16 | — | — | WO | disclosed |
| US-5174997-A | Fungicides tolerated by plants | BASF AKTIENGESELLSCHAFT (DE) | 1992-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10550089-B2 | Inhibitors of protease-activated receptor-2 | F2RL1, F2R, F2RL3 | PTGDR2 99/4885F2RL1 1/4885 |
| US-20190144394-A1 | INHIBITORS OF PROTEASE-ACTIVATED RECEPTOR-2 | F2RL1, F2R, F2RL3 | PTGDR2 99/4885F2RL1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.